Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGAIN-2
2023-508738-32-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of trastuzumab and trastuzumab emtansine in breast cancer (3 arms), sponsored by MEDSIR. Primary endpoints: 3-year recurrence-free interval and Global health status decline rate at 1 year. Planned start Sep 2024; status: authorised.
02
Drugs
trastuzumabtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508738-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508738-32-00.